Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen

  • S. Ferrone
  • X. Wang
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 158)


The realization that tumor cells utilize multiple mechanisms to escape from immune recognition and destruction has stimulated interest in developing and applying immunotherapeutic strategies which target both humoral and cellular immunity to malignant cells. As a result, the tumor-associated antigens (TAA) used as targets have to be expressed on the cell surface membrane of malignant cells. Furthermore, since most of the TAA used for active specific immunotherapy are self-antigens, a challenge facing tumor immunologists is to develop strategies which are effective in breaking tolerance to self-antigens. This chapter describes one strategy which relies on the use of peptide mimics of the human high-molecular-weight melanoma-associated antigen (HMW-MAA) as immunogens to implement active specific immunotherapy in patients with malignant melanoma. These mimics, which are isolated from phage display peptide libraries by panning with anti-HMW-MAA monoclonal antibodies, are expected to induce both humoral and cellular anti-HMW-MAA immunity.


Active Specific Immunotherapy Phage Display Peptide Library Acral Lentiginous Melanoma Peptide Mimic Human High Molecular Weight 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reisfeld RA, Cheresh DA (1987) Human tumor antigens. Adv Immuno1: 40; 323–377CrossRefGoogle Scholar
  2. 2.
    Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337–365PubMedCrossRefGoogle Scholar
  3. 3.
    Tureci O, Sahin U, Pfreundschuh M (1997) Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 3: 342–349PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity10: 281–287PubMedCrossRefGoogle Scholar
  5. 5.
    Bystryn J-C, Ferrone S, Livingston P (1993) (editors) Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 690: 1–401CrossRefGoogle Scholar
  6. 6.
    Greten TF, Jaffee EM (1999) Cancer vaccines. J Clin Oncol 17: 1047–1060PubMedGoogle Scholar
  7. 7.
    Milstein C, Waldmann H (1999) Curr Opin Immunol 11: 589–591PubMedCrossRefGoogle Scholar
  8. 8.
    Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (1999) Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol In pressGoogle Scholar
  9. 9.
    Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89: 466–470PubMedCrossRefGoogle Scholar
  10. 10.
    Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ (1994) Improved survival in AJCC stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036–1044PubMedGoogle Scholar
  11. 11.
    Maclean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against Mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19: 59–68CrossRefGoogle Scholar
  12. 12.
    Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J and the German Cancer Aid 17–1A study group (1994) Randomised trial of monocloncal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343: 1177–1183PubMedCrossRefGoogle Scholar
  13. 13.
    Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twadddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-pl85HER2/neu monoclonal antibody plus cisplatin in patients with HER/2neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659–2671PubMedGoogle Scholar
  14. 14.
    Mendelsohn J, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, Shin HJ, Metz E, Pfister D, Perez-Soler R, Lawhorn K, Matsumoto T, Gunnett K, Falcey J, Waksal H, Hong WK (1999) A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma ( SCC ). Proc Am Soc Clin Oncol 18: 389aGoogle Scholar
  15. 15.
    Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1–4PubMedCrossRefGoogle Scholar
  16. 16.
    Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187: 1163–1167PubMedCrossRefGoogle Scholar
  17. 17.
    Mittelman A, Chen GZJ, Wong GY, Liu C, Hirai S, Ferrone S (1995) Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1: 705–713PubMedGoogle Scholar
  18. 18.
    Natali PG, Imai K, Wilson BS, Bigotti A, Cavaliere R, Pellegrino MA, Ferrone S (1981) Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40 S to human melanoma cells. J Natl Cancer Inst 67: 591–601PubMedGoogle Scholar
  19. 19.
    Ferrone S, Temponi M, Gargiulo D, Scassellati GA, Cavaliere R, Natali PG (1988) Selection and utilization of monoclonal antibody defined melanoma associated antigens for immunoscintigraphy in patients with melanoma. In: Radiolabeled monoclonal antibodies for imaging and therapy, NATO ASI Series, ( Srivastava, SC, ed) Plenum Press New York and London 152: 55–78Google Scholar
  20. 20.
    Giacomini P, Natali PG, Ferrone 5 (1985) Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J Immunol 135: 696–702Google Scholar
  21. 21.
    Chattopadhyay P, Kaveri S-V, Byars N, Starkey J, Ferrone S, Raychaudhuri S (1991) Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: Characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMEL-1. Cancer Res 51: 6045–6051PubMedGoogle Scholar
  22. 22.
    Kageshita T, Kuriya N, Ono T, Horikoshi T, Takahashi M, Wong GY, Ferrone S (1993) Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res 53: 2830–2833Google Scholar
  23. 23.
    Schlingemann RO, Rietveld FJR, de Waal RMW, Ferrone S, Ruiter DJ (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136: 1393–1405Google Scholar
  24. 24.
    Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93: 9710–9715PubMedCrossRefGoogle Scholar
  25. 25.
    Bonnycastle LL, Mehroke JS, Rashed M, Gong X, Scott JK (1996) Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J Mol Biol 258: 747–762PubMedCrossRefGoogle Scholar
  26. 26.
    Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, Patrick, J, Steinbach JH, Culp W, Brandt BL (1974) Clonal cell lines from the rat central nervous system. Nature 249: 224–227PubMedCrossRefGoogle Scholar
  27. 27.
    Nishiyama A, Dahlin KJ, Prince JT, Johstone SR, Stallcup WB (1991) The primary structure of NG2, a novel membrance-spanning proteoglycan. J Cell Biol 114: 359–371PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2001

Authors and Affiliations

  • S. Ferrone
    • 1
  • X. Wang
    • 1
  1. 1.Department of ImmunologyRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations